Stock Price & Analysis

Based on the recent data and market analysis, here's a concise assessment of PFE stock:

Technical Analysis

The stock is showing signs of stabilization after a prolonged downtrend, with recent price action forming a potential base around the $26 level. The RSI-14 at 53.50 indicates neutral momentum, while the stock is trading below both its 60-day and 200-day moving averages, suggesting bearish long-term trend but potential short-term recovery.

Fundamental Outlook

• Trading at 8x forward earnings, significantly below its 5-year average P/E of 13x
• Attractive dividend yield of 6.6% with management committed to maintaining and growing dividends
• Management projects 2025 revenue between $61-64 billion and adjusted EPS of $2.80-3.00

Key Growth Catalysts

• Oncology expansion through Seagen acquisition showing early positive results
• Cost savings program on track to deliver $4.5 billion by end of 2025
• Strong pipeline with 19 product launches planned over 18 months

Risk Factors

• Patent cliff concerns with key products like Eliquis losing exclusivity by 2029
• Ongoing transition from COVID-19 revenue decline
• Political and pricing pressure in the pharmaceutical sector

Buy/Sell Recommendation Based on the current valuation, strong dividend yield, and strategic initiatives to drive future growth, PFE stock appears to be a BUY at current levels. The stock's significant undervaluation compared to historical averages provides a margin of safety, while the company's focus on oncology and pipeline development offers potential catalysts for future appreciation.

Based on the provided data and recent market analysis, here is the price prediction for PFE stock in 2025:

Pfizer's stock price is projected to reach $31-33 by end of 2025, representing a potential upside of 17-24% from current levels of $26.26. The key drivers include:

Key Growth Catalysts:

• Revenue guidance of $61-64 billion for 2025, with adjusted EPS growth of 10-18% to $2.80-3.00 per share
• Promising pipeline developments, especially in oncology and potential oral weight management drug danuglipron
• Cost savings target increased to $4.5 billion by end of 2025

Supporting Factors:

• Current valuation at 8x trailing earnings is well below 5-year average P/E of 13x
• Strong dividend yield of 6.5% provides downside protection
• Q4 2024 results exceeded estimates with revenue of $17.8B and EPS of $0.63

Risk Factors:

• Declining COVID-19 product sales impact
• Patent expirations on key drugs
• Increased competition in core markets
• Medicare pricing reform estimated $1B sales impact

The stock appears oversold at current levels and multiple expansion along with earnings growth should drive price appreciation, though near-term volatility may persist as the company transitions its portfolio.

The S1 support level for PFE Stock is $25.33 ,The R1 resistant level for PFE Stock is $26.75.

As of the end of day on 2025-02-26, the price of PFE Stock was $26.55.

The target price for PFE Stock according to analyst rating is 30.93, with the highest price target at 36.00 and the lowest at 28.00. Analysts have a Moderate Buy rating on PFE Stock overall.

The market cap of PFE is $151.5B.

Based on the provided data and recent market analysis, here's a comprehensive evaluation of PFE's valuation:

Valuation Analysis PFE is currently showing signs of undervaluation rather than overvaluation, supported by several key metrics:

1. PE Ratio Trend

• Current PE: 77.06 (Q4 2023)
• Historical comparison shows this spike is temporary due to earnings decline
• Forward PE of ~8x indicates significant undervaluation compared to historical average of 13x

2. EV/EBITDA Multiple

• Current: 11.45x (Q4 2023)
• Shows reasonable valuation compared to industry standards
• Increased from 6.8x in 2022 but still within acceptable range

Financial Health Indicators

• Revenue declined from $100.3B (2022) to $58.5B (2023)
• Net margin decreased from 31.3% to 3.7%
• However, cost savings of $4.5B targeted by end of 2025

Growth Catalysts

• 19 new product launches over 18 months
• Strategic Seagen acquisition strengthening oncology portfolio
• Pipeline includes multiple potential blockbusters in development

Market Sentiment Recent analyst ratings show mixed but generally neutral to positive outlook:

• Citigroup: $29 PT
• Guggenheim: $33 PT (Buy rating)
• B of A Securities: $29 PT

Conclusion: PFE is NOT overvalued at current levels. The stock appears undervalued considering:

1. Forward PE of 8x vs historical 13x
2. Strong pipeline and strategic acquisitions
3. Significant cost savings initiatives
4. Healthy dividend yield of 5.73%
5. Temporary earnings pressure causing misleading trailing PE

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.

Based on the provided data and market research, here's a comprehensive analysis for Pfizer's (PFE) stock price prediction for 2030:

Technical Analysis

Price Prediction Analysis for 2030

Pfizer's stock is projected to reach approximately $45-50 by 2030, representing a 70-90% increase from current levels, driven by three key factors:

1. Strong earnings growth potential of 14% annually through 2030, supported by the company's expanding oncology pipeline and strategic acquisitions like the $43 billion Seagen deal.

2. Successful transformation of revenue mix, with management expecting to double its oncology patient base by 2030 and launch at least three new blockbuster drugs generating over $1 billion each in annual sales.

3. Current attractive valuation with PEG ratio of 0.6 (anything under 1.0 is considered cheap), suggesting significant upside potential as the market eventually recognizes the company's growth prospects.

This prediction considers Pfizer's demonstrated ability to navigate patent cliffs historically, its robust pipeline particularly in oncology, and the company's commitment to maintaining and growing its dividend, which provides a floor for the stock price.

PFE has a total of 88000 employees.